Izilendustat (hydrochloride)

Izilendustat (hydrochloride) is a potent inhibitor of prolyl hydroxylase which stabilizes hypoxia inducible factor- 1 alpha (HIF- lα), as well as hypoxia inducible factor-2 (HIF-2) . Izilendustat (hydrochloride) has the potential for the research of HIF- lα related diseases including Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, anemia, colitis, and other inflammatory bowel diseases (extracted from patent WO2011057115A1/WO2011057112A1/WO2011057121A1) [1][2][3].

Product Specifications

CAS Number

[1303513-80-5]

UNSPSC

12352005

Target

HIF/HIF Prolyl-Hydroxylase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/izilendustat-hydrochloride.html

Solubility

10 mM in DMSO

Smiles

O=C(N1CCN(CC(C=CN2CC3=CC=C(Cl)C=C3)=C(O)C2=O)CC1)OC(C)(C)C.[H]Cl

Molecular Formula

C22H29Cl2N3O4

Molecular Weight

470.39

References & Citations

[1]Joseph H, et al. Prolyl hydroxylase inhibitors. Patent WO2011057115A1. |[2]Robert Shalwitz, et al. Methods for increasing the stabilization of hypoxia inducible factor-1 alpha. Patent WO2011057112A1.|[3]Joseph H, et al. Compositions and methods for treating colitis. Patent WO2011057121A1.